Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.2 million.

  • Arrowhead Pharmaceuticals' Net Income towards Common Stockholders rose 11611.82% to $28.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $233.5 million, marking a year-over-year increase of 13595.3%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders stood at $28.2 million, which was up 11611.82% from $16.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders registered a high of $367.8 million during Q1 2025, and its lowest value of -$178.7 million during Q2 2025.
  • In the last 5 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$67.7 million in 2021 and averaged -$52.9 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders crashed by 36637.3% in 2024 and then skyrocketed by 38962.8% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Net Income towards Common Stockholders stood at -$62.9 million in 2021, then skyrocketed by 33.5% to -$41.8 million in 2022, then plummeted by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then skyrocketed by 116.12% to $28.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at $28.2 million for Q4 2025, versus $16.1 million for Q3 2025 and -$178.7 million for Q2 2025.